Scythian Biosciences Corp. engages in development of drug therapies. It specializes in the development of a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury. It also intends to develop other potential cannabinoid and non-cannabinoid based pharmaceutical products, including one that is in development for treatment of gastro-inflammatory disease. The company is headquartered in Toronto, Canada.